DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Pharmacological Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 bioactive compounds, each approved by regulatory agencies such as the FDA, EMA, HMA, CFDA, or PMDA, and is optimized for high-throughput screening (HTS) and high-content screening (HCS) applications. All compounds are supplied as 10 mM DMSO solutions, stable for up to 24 months at -80°C, facilitating robust and reproducible experimentation (ApexBio product page). The library supports drug repositioning, pharmacological target identification, and mechanistic studies in oncology, neurodegeneration, and virology (Sigurdardóttir et al., 2024). Automated cellular assays using this library identify novel inhibitors, including those with unique covalent or allosteric mechanisms. The resource enables translational workflows by integrating with standard microplate formats and supporting advanced assay designs (Related resource).

Biological Rationale

The use of FDA-approved drug libraries in biomedical research is grounded in drug repurposing principles. Compounds with established clinical safety profiles can be rapidly redeployed for new indications (Sigurdardóttir et al., 2024). High-throughput screening of such libraries enables the discovery of modulators for diverse biological targets, including viral proteases, kinases, G protein-coupled receptors (GPCRs), and enzyme pathways. The DiscoveryProbe™ FDA-approved Drug Library leverages these principles by providing a standardized, comprehensive set of well-characterized molecules for efficient screening. This approach accelerates the pipeline from initial target validation to translational research (PrecisionFDA, 2023).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The compounds in the DiscoveryProbe™ FDA-approved Drug Library represent a broad array of mechanisms, including:

• Receptor agonists and antagonists (e.g., metformin as an AMPK activator)
• Enzyme inhibitors (e.g., doxorubicin as a topoisomerase II inhibitor)
• Ion channel modulators (e.g., nifedipine as a calcium channel blocker)
• Signal pathway regulators (e.g., atorvastatin as an HMG-CoA reductase inhibitor)
• Covalent and allosteric inhibitors (e.g., bortezomib as a proteasome inhibitor)

Each compound's mechanism is annotated in the library documentation, facilitating rational selection for target-based or phenotypic screens. Cellular assays using this library can identify compounds that are bioavailable, stable within cells, and selectively active against intracellular targets (Sigurdardóttir et al., 2024).

Evidence & Benchmarks

• In a yeast-based genetic screen, eight small molecules from a library of ~2,500 compounds—including FDA-approved drugs—were identified as SARS-CoV-2 MPro inhibitors, with five being known proteasome inhibitors (DOI).
• Boron-containing proteasome inhibitors (bortezomib, delanzomib, ixazomib) were confirmed as covalent inhibitors of MPro in non-standard buffers, highlighting the importance of assay context (DOI).
• The DiscoveryProbe™ FDA-approved Drug Library (L1021) is formatted as 10 mM DMSO solutions in 96-well or deep-well plates, ensuring compatibility with automated liquid handling systems (Product page).
• Compounds remain stable for 12 months at -20°C and 24 months at -80°C, supporting long-term research projects (Product documentation).
• Drug repositioning screens using this library have identified candidates for oncology, infectious diseases, and neurodegenerative disorders (AKTPathway, 2022).

This article extends the analysis provided in 'DiscoveryProbe™ FDA-approved Drug Library: Unveiling Covalent Inhibitor Discovery' by incorporating the latest evidence from cell-based viral protease studies and clarifying conditions where covalent inhibitors are reliably detected.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library enables:

• High-throughput screening (HTS) for target-based or phenotypic drug discovery
• Drug repositioning and secondary indication exploration
• Pharmacological target identification and pathway mapping
• Cancer and neurodegenerative disease research
• Signal pathway regulation and enzyme inhibitor screening

As evidenced by Sigurdardóttir et al., this library is particularly effective for identifying cell-permeable, bioactive inhibitors that may be missed in conventional in vitro enzymatic assays (DOI).

Common Pitfalls or Misconceptions

• Not all in vitro hits translate to cellular efficacy; cell permeability and stability are critical (DOI).
• Boron-containing inhibitors may require non-standard buffer conditions for activity; standard enzymatic buffers can yield false negatives (DOI).
• The library is not designed for direct clinical use; compounds are for research applications only.
• General cytotoxicity does not equate to target specificity; positive selection assays filter out non-specific toxic compounds.
• Compound solubility and storage temperature must be maintained as per documentation to avoid degradation (Product page).

Workflow Integration & Parameters

All compounds are provided pre-dissolved in DMSO at 10 mM, compatible with standard 96-well and deep-well microplate formats, and 2D barcoded storage tubes. Shipping is performed on blue ice for evaluation samples, with room temperature or blue ice options for larger orders. The recommended storage is -20°C for up to 12 months or -80°C for up to 24 months (DiscoveryProbe™ FDA-approved Drug Library).

Automated liquid handling and robotic screening platforms are directly compatible. Assay design should consider compound stability, membrane permeability, and buffer conditions, especially for covalent or redox-sensitive inhibitors (EPGLabs, 2024). This article clarifies workflow integration parameters compared to previous reports by specifying stability and storage requirements in detail.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a robust, standardized resource for high-throughput and high-content screening. Its breadth, regulatory compliance, and validated performance position it as a key tool for drug repositioning, target identification, and mechanistic research. Recent evidence demonstrates the necessity of cellular and context-specific assays to reveal true bioactivity, particularly for covalent and allosteric inhibitors. Ongoing integration with advanced robotic workflows and data analytics platforms will further enhance its impact in translational and precision medicine research (PrecisionFDA, 2023).